Document is current

Any future updates will be listed below

Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada

Crossref DOI link: https://doi.org/10.1007/s40273-014-0241-z

Published Online: 2014-12-09

Published Print: 2015-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark